Patel Partha, Rahman Syed Minhaj, Behroozian Tara, Finkelstein Samuel, Kanee Lauren, Zhang Elwyn, Banerjee Suvam, Aquilano Michele, Bonomo Pierluigi, Chan Raymond J, Chow Edward, Chan Adrian Wai, Yee Kwan Jennifer Yin, Lee Shing Fung, Wong Henry, van den Hurk Corina, Trombetta Mark, Ryan Wolf Julie
Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
University of Rochester School of Medicine & Dentistry, Rochester, NY, USA.
Clin Transl Radiat Oncol. 2025 May 9;53:100977. doi: 10.1016/j.ctro.2025.100977. eCollection 2025 Jul.
Acute radiation dermatitis (ARD) is a common adverse effect experienced by patients undergoing radiation therapy. Effective assessment tools to accurately measure and manage ARD's impact on patients' quality of life and treatment outcomes is needed. The aim of this study was to evaluate the diverse tools and outcome measures used in the assessment of ARD. A systematic review of MEDLINE®, Embase, and Cochrane was conducted for records 1946-March 2024. A total of 423 studies, including 227 randomized controlled trials (RCTs), were included in the analysis. The review identified 58 distinct tools utilized in the assessment of ARD including clinician and patient-reported outcomes, quality-of-life instruments, and biophysical measures. The most frequently employed tools were the Radiation Therapy Oncology Group criteria, Common Terminology Criteria for Adverse Events, Skindex-16, Visual Analogue Scale, Dermatology Life Quality Index, European Organization for Research and Treatment of Cancer Quality of Life C30, Radiation-Induced Skin Reaction Assessment Scale, Skin Toxicity Assessment Tool, photography, reflectance spectrophotometry, and the corneometer. This investigation into ARD assessment tools reveals a broad application of instruments but is limited by a pervasive lack of consensus, preventing the endorsement of a standardized toolset. The variability in tool use necessitates further research, particularly high-quality RCTs, to establish validated and reliable measures. Future publications, including Delphi consensus-based recommendations, are anticipated to address these gaps, aiming to standardize ARD assessment methodologies.
急性放射性皮炎（ARD）是接受放射治疗的患者常见的不良反应。需要有效的评估工具来准确测量和管理ARD对患者生活质量和治疗结果的影响。本研究的目的是评估用于ARD评估的各种工具和结果指标。对MEDLINE®、Embase和Cochrane进行了系统综述，检索1946年至2024年3月的记录。分析共纳入423项研究，包括227项随机对照试验（RCT）。该综述确定了58种用于ARD评估的不同工具，包括临床医生和患者报告的结果、生活质量工具和生物物理测量方法。最常用的工具是放射治疗肿瘤学组标准、不良事件通用术语标准、Skindex-16、视觉模拟量表、皮肤病生活质量指数、欧洲癌症研究与治疗组织生活质量C30、放射性皮肤反应评估量表、皮肤毒性评估工具、摄影、反射分光光度法和角质计。对ARD评估工具的这项调查揭示了这些工具的广泛应用，但受到普遍缺乏共识的限制，无法认可一套标准化的工具集。工具使用的变异性需要进一步研究，特别是高质量的RCT，以建立经过验证和可靠的测量方法。预计未来的出版物，包括基于德尔菲共识的建议，将填补这些空白，旨在使ARD评估方法标准化。
